Trial Profile
A Multicenter, Open Label Phase I/II Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma (MM) Patients
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 29 Jun 2023 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 18 Aug 2021 Planned End Date changed from 1 Jun 2021 to 1 Dec 2021.